Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update
JERSEY CITY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today reported financial results for the year ended December 31,
View HTML
Toggle Summary SCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference
JERSEY CITY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29 th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT.
View HTML
Toggle Summary SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA's request
Ongoing and future clinical development using the oral formulation of SCY-078 are unaffected
View HTML
Toggle Summary SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences: Canaccord Genuity Rare Disease Conference at the InterContinental New York Barclay Hotel in
View HTML
Toggle Summary SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors
— Former Chief Operating Officer of Medivation adds broad experience in commercial, strategy, operations and business development — —  SCYNEXIS to ramp up commercial preparatory and territorial licensing activities for its lead product, SCY-078 — JERSEY CITY, N.J., Jan.
View HTML
Toggle Summary SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
— Regimen of intravenous (IV) formulation of SCY-078 successfully identified and characterized to support subsequent studies — — Long-term toxicology studies completed, confirming favorable safety profile of oral SCY-078 — JERSEY CITY, N.J., Dec.
View HTML
Toggle Summary SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
JERSEY CITY, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic needs, today announced that the Company will participate in the Guggenheim Securities 4 th Annual Boston
View HTML
Toggle Summary SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal  Activity and Favorable Safety Profile of  SCY-078 -- -- Company is Well Positioned and Capitalized to Accelerate and Expand Clinical Development of SCY-078 in Multiple Indications -- JERSEY CITY,
View HTML
Toggle Summary SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078
SCY-078 demonstrates a low potential for certain drug-drug interactions — a relevant differentiator versus the azoles, the leading antifungal class — providing an opportunity for favorable labeling Significant step forward to further de-risk the ongoing development program of SCY-078
View HTML
Toggle Summary SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan
Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida Infections Well-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis Patients Evidence of Efficacy and Lower Relapse Rates versus Standard of Care in VVC Patients Strong Cash Position
View HTML